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Abstract
Background: Alveolar rhabdomyosarcoma (ARMS) has a high propensity to metastasize, leading to its aggressiveness
and a poor survival rate among those with the disease. More than 80% of aggressive ARMSs harbor a PAX3-FKHR fusion
transcription factor, which regulates cell migration and promotes metastasis, most likely by regulating the fusion
protein’s transcriptional targets. Therefore, identifying druggable transcription targets of PAX3-FKHR that are also
downstream effectors of PAX3-FKHR–mediated cell migration and metastasis may lead to novel therapeutic approaches
for treating ARMS.
Methods: To identify genes whose expression is directly affected by the level of PAX3-FKHR in an ARMS
cellular-context, we first developed an ARMS cell line in which PAX3-FKHR is stably down-regulated, and
showed that stably downregulating PAX3-FKHR in ARMS cells significantly decreased the cells’ motility. We
used microarray analysis to identify genes whose expression level decreased when PAX3-FKHR was
downregulated. We used mutational analysis, promoter reporter assays, and electrophoretic mobility shift
assays to determine whether PAX3-FKHR binds to the promoter region of the target gene. We used siRNA
and pharmacologic inhibitor to downregulate the target gene of PAX3-FKHR and investigated the effect of
such downregulation on cell motility.
Results: We found that when PAX3-FKHR was downregulated, the expression of carnitine palmitoyltransferase
1A (CPT1A) decreased. We showed that PAX3-FKHR binds to a paired-domain binding-site in the CPT1A
promoter region, indicating that CPT1A is a novel transcriptional target of PAX3-FKHR. Furthermore,
downregulating CPT1A decreased cell motility in ARMS cells, indicating that CPT1A is a downstream effector of
PAX3-FKHR–mediated cell migration and metastasis.
Conclusions: Taken together, we have identified CPT1A as a novel transcriptional target of PAX3-FKHR and
revealed the novel function of CPT1A in promoting cell motility. CPT1A may represent a novel therapeutic
target for the treatment of ARMS.
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Background
Rhabdomyosarcoma (RMS) is the most common soft
tissue sarcoma in children. Two subtypes of RMS have
been identified on the basis of histopathologic features—
embryonal (ERMS) and alveolar (ARMS)—each with dis-
tinct clinical and genetic characteristics. Most of the more
aggressive ARMSs are associated with either a 2;13 or a
1;13 chromosomal translocation, generating PAX3-FKHR
and PAX7-FKHR fusion products, respectively. The
unique expression, function, and subcellular location of
the fusion proteins contribute to their oncogenic behavior
by modifying cell growth, differentiation, and migration
[1].
ARMS has a high propensity to metastasize. Preventing
metastasis is an important therapeutic approach to cancer
treatment, and evidence shows that PAX3-FKHR may
regulate cell migration, thus promoting a metastatic
phenotype. Specifically, downregulating PAX3-FKHR in
ARMS cells decreases cell migration and cell invasion [2].
In a preclinical mouse model of ARMS, the expression
level of PAX-FKHR was low in preneoplastic skeletal
muscle, but was >100-fold higher in ARMS tumors.
Metastatic ARMS tumors expressed PAX3-FKHR at incre-
mentally higher levels than the primary tumors, further
demonstrating the roles of PAX3-FKHR in promoting
tumor metastasis [3]. Although it is possible to prevent
ARMS metastasis by downregulating PAX3-FKHR, tran-
scription factors are challenging drug targets, and cur-
rently there is no pharmacologic inhibitor of PAX3-FKHR
available. Therefore, identifying druggable transcription
targets of PAX3-FKHR that are also downstream effectors
of PAX3-FKHR–mediated cell migration and metastasis
may lead to novel therapeutic approaches for treating
ARMS.
Significant effort has been made to identify transcription
targets of PAX3-FKHR, and several transcription targets of
PAX3-FKHR that are involved in ARMS cell migration
have been reported [4,5]. Although these studies have led
to the identification of genes whose expression appears to
be regulated by PAX3-FKHR in each individual study, very
few genes have been identified in multiple studies, possibly
due to the model systems used. In the present study, we
use an ARMS model to identify genes whose expression is
directly affected by the level of PAX3-FKHR in an ARMS
cellular-context under physiologically relevant conditions.
We have identified carnitine palmitoyltransferase 1A
(CPT1A) as a novel PAX3-FKHR transcription target that
also mediates the function of PAX3-FKHR in regulating
cell motility.
CPT1 is anchored in the outer membrane of mitochon-
dria and catalyzes the formation of long chain acyl-
carnitine, which will then traverse the inner mitochondrial
membrane and undergo β-oxidation in the mitochondria.
Three isoforms of CPT1 have been identified: CPT1A,
which is detected in many tissues and the most abundant
in the liver; CPT1B, which is predominantly expressed in
muscle; and CPT1C, which is mainly present in the brain.
Knockouts of CPT1A and CPT1B are lethal [6,7], therefore
the exact role of CPT1A or CPT1B in energy homoeostasis
remains unresolved. CPT1C is not an essential gene in
mice although the animals exhibit reduced fatty acid
oxidation when CPT1C is knocked-out [8,9]. Although the
precise role of CPT1 in tumor growth remains unknown, a
recent study showed that CPT1C is frequently expressed
in tumors and up-regulated in response to metabolic
stress. Furthermore, CPT1C depletion reduced tumor
growth in xenograft models [10]. Currently, how the ex-
pression of CPT1 is regulated in ARMS, and whether
CPT1 plays a role in ARMS tumorigenesis or contributes
to the aggressive metastatic behavior of ARMS have not
yet been investigated. In this study, we establish that
CPT1A is a transcription target of PAX3-FKHR. In
addition, for the first time, we report that CPT1A regulates
cell motility in ARMS cancer cells. Therefore, CPT1A is a
transcription target of PAX3-FKHR and a downstream
effector of PAX3-FKHR–mediated cell migration and
metastasis, and may represent a therapeutic target for
ARMS. Defining the regulation of CPT1A by PAX3-FKHR
may facilitate the validation of CPT1A as a therapeutic tar-
get for treating ARMS.
Methods
Cell culture
Rh30, Rh41, RD, HEK293T, and NIH3T3 cells have been
described previously [11,12]. All cells were cultured in an
incubator with a humidified atmosphere maintained at 5%
CO2 and 95% air at 37°C. Cells were split every 3 days at
90% to 95% confluency. Phenol red–free DMEM
(Invitrogen, Carlsbad, CA) was used for all luminescence
assays.
Establishment of PAX3-FKHR–knockdown stable clones
Kikuchi et al [2] identified specific target sequence of PAX3-
FKHR (GCCTCTCACCTCAGAATTC) and designed corre-
sponding siRNA (GCCUCUCACCUCAGAAUUC) to spe-
cifically target PAX3-FKHR without affecting either PAX3 or
FKHR. A control siRNA (CUACUAUACCGAUACUCCC)
was used as a non-targeting control in their studies [2]. In
order to stably knock-down PAX3-FKHR, identical DNA
sequence (GCCTCTCACCTCAGAATTC for PAX3-FKHR;
CTACTATACCGATACTCCC for control) was synthesized
and subcloned into the pSUPER.retro.puro vector (Oligo-
Engine, Seattle, Washington) according to the manufac-
turer’s protocol. The resulting constructs were transfected
into Phoenix packaging cells (Orbigen, San Diego, CA) by
using FuGENE 6 (Invitrogen). Viral particles were collected
72 hours after transfection and transduced into Rh30 cells.
Puromycin (Invitrogen; 1 μg/mL) was used to select stable
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clones for both non-targeting control (CON) and PAX3-
FKHR knock-down (KD). KD1 and KD2 are two stable
clones from the same vector-based siRNA targeting PAX3-
FKHR, and have the same growth rate (Additional file 1:
Figure S1).
Real-time reverse transcription– polymerase chain
reaction (RT-PCR)
Real-time RT-PCR was used to measure the levels of
mRNA. Extraction of total RNA from cellular lysates,
preparation of cDNA, the PAX3-FKHR and glucose-6-
phosphate dehydrogenase (GAPDH) primers for PCR,
and the conditions for PCR have been described previ-
ously [11]. CPT1A sense primer: TCCAGTTGGCTTA
TCGTGGTG and anti-sense primer: CTAACGAGGG
GTCGATCTTGG. Real-time PCR was performed by
using an iCycler iQ real-time PCR detection system
(Bio-Rad, Hercules, CA). The mRNA levels were quanti-
fied as previously described [13]. Briefly, the cycle thresh-
old (Ct) values of each gene of interest and of GAPDH
were calculated for each sample and then the normalized
value was derived by subtracting the Ct value of GAPDH
from that of the gene of interest (ΔCt). Data are shown as
mRNA fold change (2-ΔΔCt) relative to the mRNA level of
the corresponding transcript in the control samples as
indicated.
Western blot
Cells were washed once with cold PBS, harvested by
scraping, and lysed with RIPA Buffer containing a
protease and phosphatase inhibitor cocktail (Thermo
Scientific, Rockford, IL). Lysates (20 μg/lane) were
loaded into each lane of an SDS–polyacrylamide gel;
proteins were transferred onto a nitrocellulose
membrane after size separation and analyzed by
using specific antibodies. Anti-FKHR antibodies (H-
128; sc-11350) and anti-GFP antibodies (sc-9996)
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA); anti-actin antibodies (A5441) were
obtained from Sigma (St. Louis, MO); anti-CPT1A
antibodies is a gift from Drs. Janos Kerner and
Charles Hoppel [14].
Soft agar colony formation assay
The soft agar colony formation assay was performed as
previously described by us [12] and others [15], by using
the CytoSelect 96-well Cell Transformation Kit (Cell
Biolabs, San Diego, CA). Briefly, cells were incubated
8 days in a semisolid agar media before being solubilized,
lysed, and detected by using the patented CyQuant GR
Dye and an EnVision plate reader (PerkinElmer,
Waltham, MA).
Transient transfections of siRNAs and plasmids
A PAX3-FKHR–specific siRNA (PF siRNA) and control
non-targeting siRNA (NT siRNA) were synthesized as
described previously [11]. Pooled CPT1A siRNA (ON-
TARGETplus SMARTpool L-009749-00-0005), individual
CPT1A siRNA 1 (J-009749-07-0005), and individual
CPT1A siRNA 2 (J-009749-09-0005) were obtained from
Thermo Scientific (Thermo Scientific, Chicago, IL). Cells
were plated in a 24-well plate 24 hours prior to transfec-
tion with siRNAs (10 nM) by using lipofectamine
RNAiMAX reagent (Invitrogen), or plasmids by using
FuGENE 6 (Invitrogen) according to manufacturer’s
instructions. For cell growth, cells were monitored con-
tinuously after transfection. Wound healing assays were
performed 24 hours after transfection. For evaluation of
expression levels, cells were harvested 48 hour post-
transfection.
Scratch wound-healing and cell growth assays
The wound healing assay was performed to monitor and
quantify cell motility. Briefly, cells were seeded in a 24-well
plate (Essen ImageLock plate) at 1 × 105 cells per well and
allowed to reach confluence before the surface was uni-
formly scratched across the center of well by using a Essen
wound maker provided by IncuCyte. The wells were then
rinsed with fresh media to remove floating cells, and the
wound healing process was monitored continuously by
using the IncuCyte live-cell imaging system (Essen
BioScience, Ann Arbor, Michigan). Images were obtained
at each set time point and then analyzed to quantify
wound healing by using the IncuCyte scratch wound assay
software according to the manufacturers’ instructions.
Data were expressed as % wound confluence as defined by
the integrated metrics used to quantify the wound healing
in the CellPlayer Cell Migration Assay of IncuCyte [16,17].
The CPT1A inhibitor Etomoxir was obtained from Sigma.
Cell growth was measured also by using the IncuCyte sys-
tem [18]. Briefly, cells were plated into 96-well or 24-well
plate and allowed to grow for 24 hours with or without
subsequent transfection, before acquiring phase-contrast
images and an integrated confluence metric as a surrogate
for cell number every 4 hours by IncuCyte.
Luciferase reporter assay
Three tandem copies of each CPT1A putative PAX3-
FKHR binding site, either wild-type (ie, PRO1, PRO2,
PRO3, and PRO4) or with the corresponding PD site
mutated (ie, PRO1m, PRO2m, PRO3m, and PRO4m),
were placed upstream of a minimal thymidine kinase
(tk) promoter [12] in the pGL4.20 reporter construct
(Promega, Madison, WI). The resulting oligonucleo-
tide sequences were as follows: PRO1, 5′-attacctgcctc
tctcgttctccttcattacctgcctctctcgttctccttcattacctgcctctctcg
ttctccttc-3′;PRO1m,5′-attacctgcctctctcatttaccttcattacct












NIH3T3 cells were co-transfected with pcDNA3 or
pcDNA3-PAX3-FKHR [11], one of the firefly luciferase
reporters (pGL4.20-PRO) described above, and a consti-
tutively-expressed Renilla luciferase reporter (PRL-TK,
control for transfection efficiency) (Promega) by using
FuGENE 6 according to the manufacturer’s instructions.
Then, 24 hours after transfection, 10 000 cells were pla-
ted in each well of a 96-well culture plate and grown for
an additional 24 hours before luciferase activity was mea-
sured by using the Dual-Glo Luciferase Assay System
(Promega) according to the manufacturer’s instructions.
The firefly luciferase activity was normalized to that of
Renilla luciferase.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed by using either nuclear extract or
in vitro–translated protein. To prepare nuclear extract,
HEK293T cells were transfected with either GFP–PAX3-
FKHR–expressing vector [12] or GFP control vector.
Transfected cells were harvested 48 hours later, and nu-
clear extracts were prepared by using the NE-PER*
Nuclear and Cytoplasmic Extraction Kit (Thermo Scien-
tific). To prepare in vitro–translated protein, pcDNA3-
PAX3-FKHR was used to synthesize PAX3-FKHR protein
by using TNT-Coupled Wheat Germ Extract Systems
(Promega). EMSA was performed by using the LightShift
Chemiluminescent EMSA kit (Thermo Scientific) accord-
ing to the manufacturer’s instructions. Briefly, 3 μL of nu-
clear extract or in vitro–translated protein was incubated
at room temperature for 20 min in a 20-μL volume con-
taining 2.5% glycerol, 5 mM MgCl2, 50 ng/μL Poly (dI.dC),
0.05% NP-40, and biotin end-labeled CPT1A PRO2 with
or without unlabeled PRO2 or PRO2m as indicated. Com-
plexes were resolved using electrophoresis through a 5%
native polyacrylamide gel.
Microarray
Untransfected parental Rh30 cells (WT), Rh30 control
clone (CON) and Rh30 clone with PAX3-FKHR stably
knocked down (KD1) were used to identify transcriptional
targets of PAX3-FKHR in the microarray assays. Total
RNAs were amplified and labeled by using an Agilent
Quick Amp labeling kit (part number 5190–0444, Santa
Clara, CA) and following the two color protocol (v.5.7).
We used the Agilent 4 × 44 K whole human genome
oligo microarray (G4112F, AMADID #014850) that
contains 45,015 features representing about 41,000
unique probes. Microarrays were scanned by using an
Agilent scanner (G2565CA) at 3 μm resolution, and data
were extracted by Agilent Feature Extraction software
(v. 10.5.1.1). Lowess normalization on background-
subtracted signal intensity was performed to correct the
intensity bias, and dye bias was further corrected by a
pair of dye swap experiments for each comparison. A list
of differentially expressed genes (see Additional file 2:
Table S1) were selected according to the following
criteria: 1) an average of at least 2-fold expression
change was detected in 2 comparisons (KD1 vs. WT and
KD1 vs. CON), each with 2 biological replicates includ-
ing a pair of dye-swap experiments; 2) the observed
signal intensity was greater than the value of the 99th
percentile of those of the negative controls in at least
one channel; and 3) the differential expression was con-
sistent between the dye-swap pairs in all comparisons.
Statistical analysis
Results are expressed as the mean ± SD of at least 3 inde-
pendent experiments. The Student’s t-test was used to
determine the statistical significance of the difference
between the paired samples. Differences were considered
significant if p< 0.05 (*), 0.01 (**) or 0.001 (***) and non-
significant (ns) if p> 0.05. Where applicable, sample pairs
were noted in brackets.
Results
PAX3-FKHR promotes cell motility in ARMS cells
To study the role of PAX3-FKHR in regulating ARMS cell
growth and motility, PAX3-FKHR was stably knocked
down in human ARMS cell line Rh30. As shown in
Figure 1A, both mRNA (left panel) and protein levels
(right panel) of PAX3-FKHR in the knockdown clones
(KD1 and KD2, two stable clones generated from the same
RNAi) were noticeably downregulated compared to a con-
trol clone (CON). In agreement with previously reported
results [2], downregulation of PAX3-FKHR decreased the
rate of cell growth (Additional file 1: Figure S1; KD1 and
KD2 have the same growth rate); the transformation po-
tential of these cells was decreased by 73%, as observed in
a soft agar colony formation assay (Figure 1B).
To evaluate the effect of downregulating PAX3-FKHR
on cell motility, we used a wound-healing assay. As
shown in Figure 2A, downregulating PAX3-FKHR,
either stably (KD1), or transiently (CON_PF_siRNA) by
using a specific siRNA against PAX3-FKHR (PF siRNA),
decreased cell motility compared to that of the Rh30
control clone (CON) by 37% and 61%, respectively. The
decreased cell motility in the PAX3-FKHR knocked-
down clone (KD1) can be rescued by transiently
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introducing PAX3-FKHR ectopically back into the Rh30
KD clone (Figure 2B). Figure 2C shows representative
microscopic images of newly created wounds in Rh30
control clone and KD1 clone cells and the repaired
wounds 30 hours later. Similar observations were made
when KD2 was used (data not shown). Our observations
are consistent with previous studies using either Rh4
[19] or Rh18 ARMS cells [20], confirming that PAX3-
FKHR regulates ARMS cell proliferation, transformation
potential and motility. Importantly, our data indicate
that Rh30 and its PAX3-FKHR knocked-down clone
(KD1) is an appropriate pair of cell models for the stud-
ies of PAX3-FKHR function, including transcriptional
regulation of its target genes.
PAX3-FKHR regulates the expression of CPT1A in ARMS
cells
We hypothesized that the defective cell motility in KD1
was caused by the decreased expression of one or more
of PAX3-FKHR’s target genes. To identify the target
genes of PAX3-FKHR, we compared the mRNA profiles
in KD1 with those in either Rh30 or CON by using
microarray analysis (Geo no. GSE35862; also see Meth-
ods section for a detailed description of selection cri-
teria). Among the 126 genes with at least 2-fold
expression change, 96 were downregulated in KD1 clone
(see Additional file 2: Table S1), including cannabinoid
receptor 1 (CNR1), which has been previously reported
as a PAX3-FKHR target gene in multiple studies [1], and
ALDH1A3, EYA2, MCTP2, MXRA5, NTF3, OLIG1,
SEPP1, SULF2, and TOX3, which were recently identified
as PAX3-FKHR target genes in ARMS cell line Rh4 [21].
CPT1A was identified as a gene whose expression in
KD1 is significantly downregulated (an average of 8-fold
reduction) compared to that in wild-type Rh30 cells or
Rh30 control clone cells. To confirm that the reduced
CPT1A expression was correlated to the decreased PAX3-
FKHR expression, Rh30 cells were transiently transfected
with PF siRNA; the downregulation of PAX3-FKHR (97%
reduction at mRNA level) led to a downregulation of
CPT1A mRNA (70% reduction) (Figure 3A) and protein















Figure 1 Downregulation of PAX3-FKHR decreases anchorage-independent growth of Rh30 cells. (A) shRNA against PAX3-FKHR
downregulates the level of PAX3-FKHR. Rh30 cells stably transfected with either shRNA against PAX3-FKHR (KD1 and KD2, two different clones
generated from the same shRNA) or a control non-targeting shRNA (CON) were used to analyze PAX3-FKHR mRNA or protein levels by using
real-time RT-PCR (left panel) or Western blotting (right panel), respectively. GAPDH was used as an internal control for RT-PCR experiments, and
PAX3-FKHR mRNA levels in KD1 and KD2 were normalized to CON (PF mRNA fold-change). Actin was the equal loading control for Western blot
experiments. M, molecular weight marker; PF, PAX3-FKHR (~99kD); FKHR (~70kD) was also indicated. (B) Downregulation of PAX3-FKHR decreases
anchorage-independent growth of Rh30. Raw fluorescent units (RFUs) were used to represent colony numbers of Rh30 control clone (CON) and
KD1; and the average of triplicate measurements is shown.
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ARMS cell line, Rh41 (Figure 3A). Additionally, both the
mRNA (Figure 3A) and protein levels (Figure 3B) of
CPT1A are very low in RD, a PAX3-FKHR–negative
human ERMS cell line. When PAX3-FKHR is transfected
into either RD or NIH3T3 cells, CPT1A levels are moder-
ately induced (Figure 3B and 3C). These results suggested
that CPT1A might be a transcriptional target of PAX3-
FKHR.
Induction of CPT1A transcription by PAX3-FKHR involves a
paired-box domain (PD) binding site-dependent
transactivation
To investigate whether PAX3-FKHR controls CPT1A
transcription by binding to CPT1A’s promoter, we
analyzed the DNA sequence 5′ to the CPT1A tran-
scription start site and identified 3 putative PAX3-
FKHR binding sites that matched the consensus
composite sequence: a paired-box domain (PD) bind-
ing site (GTTC/AT/C) followed by a linker sequence
and a homeodomain (HD) binding site (ATTA) (Fig-
ure 4A). For comparison, we also included PRO1, a
sequence that contains an HD binding site followed
by a PD binding site in our analysis. To investigate
the contribution of these putative PAX3-FKHR bind-
ing sites to the transactivation of CPT1A, we gener-
ated 4 luciferase reporter constructs: PRO1-tk-luc,
PRO2-tk-luc, PRO3-tk-luc and PRO4-tk-luc (Fig-













Figure 2 Downregulation of PAX3-FKHR decreases the motility of Rh30 cells. (A) Motility of Rh30 cells control clone (CON) decreases when
PAX3-FKHR is either stably knocked down (KD1) or transiently knocked down (CON_PF siRNA). The protein levels of PF were shown below the bar
graph. The wound confluence of CON was arbitrarily set as 100%. (B) The decreased cell motility of KD1 can be rescued by transiently expressing
pcDNA3-PAX3-FKHR (KD1_pcDNA3-PF) but not by expressing an empty vector (KD1_pcDNA3). The protein levels of PF in KD1 transfected with
pcDNA3 or pcDNA3-PF were shown below the bar graph. Rh30 control clone (CON) was shown as a reference. PAX3-FKHR siRNA (PF siRNA) or
plasmids (either pcDNA3 or pcDNA3-PF) were transfected into CON (CON_PF siRNA) in (A) or KD1 (pcDNA3 or pcDNA3-PF) in (B) 24 hours before
real-time monitoring of wound healing. The data, expressed as % Wound Confluence, represent the quantitation of wound healing 30 hours after
the scratch was created. (C) Representative microscopic images taken 30 hours after the scratch was created.
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negative cell line commonly used to evaluate the
function of PAX3-FKHR [22], ectopic expression of
PAX3-FKHR substantially transactivated PRO2-tk-luc (57%
increase) and PRO3- tk-luc (42% increase), only slightly
transactivated PRO1-tk-luc (17% increase), and failed to
transactivate PRO4-tk-luc, suggesting that PRO2, PRO3,
and possibly PRO1 might contain the binding element for
PAX3-FKHR. To confirm this, we mutated the putative
PD-binding site in each reporter construct to generate
PRO1m-tk-luc, PRO2m-tk-luc, PRO3m-tk-luc, and
PRO4m-tk-luc (Figure 4A) and then tested the responses
of each to PAX3-FKHR expression. As shown in Figure 4B,
mutating the PD-binding site in PRO2 abolished its
transactivation by PAX3-FKHR. Mutating the PD-bind-
ing site in PRO1 and PRO3 not only abolished the
reporters’ transactivation by PAX3-FKHR but also
decreased their basal activities (65% decrease for PRO1
and 69% decrease for PRO3), possibly because the basal
activation of PRO1 and PRO3 is primarily mediated by
mechanism independent of PAX3-FKHR. The require-
ment of an intact PD binding site for PAX3-FKHR–
mediated transactivation is consistent with previous
reports [5,21,23]. Our data suggest that the promoter re-
gion of CPT1A contains the binding sites for PAX3-
















































Figure 3 PAX3-FKHR regulates the expression of CPT1A. Levels of CPT1A and PAX3-FKHR mRNA were determined by using quantitative real
time RT-PCR or Western blot. (A) The mRNA levels of PAX3-FKHR or CPT1A in control Rh30 cells was arbitrarily set as 1, and the mRNA levels of
PAX3-FKHR or CPT1A measured under other experimental conditions were expressed as “mRNA fold change” by normalizing them to the
corresponding mRNA level in Rh30 cells. Rh30_PF siRNA, Rh30 cells transiently transfected with PF siRNA; Rh41_PF siRNA, Rh41 transiently
transfected with PF siRNA. Rh30_NT siRNA, Rh41_NT siRNA, and RD represents Rh30, Rh41, and RD cells transiently transfected with NT siRNA,
respectively. (B) Protein levels of PAX3-FKHR (GFP-PF and PF) and CPT1A in cells (NIH3T3 or RD) transiently transfected with either GFP or GFP-PF,
or Rh30 transiently transfected with either NT siRNA or PF siRNA. Actin was an equal loading control. (C) RD or NIH3T3 cells were transiently
transfected with either GFP empty vector or GFP-PAX3-FKHR (GFP-PF). The mRNA levels of CPT1A in 3T3/GFP or RD/GFP was arbitrarily set as 1.
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PAX3-FKHR participates in regulating CPT1A transcription
We next investigated whether PAX3-FKHR interacts with
the promoter region of CPT1A by performing an in vitro
electrophoretic mobility shift assay (EMSA). As shown in
Figure 5A, biotin-labeled wild-type PRO2 probe (lane 1)
was shifted by the addition of nuclear extract from
HEK293T cells transfected with GFP-PAX3-FKHR (lane 2),
but not by nuclear extract from HEK293T cells transfected
with a control vector (GFP only) (lane 3), indicating the for-
mation of a specific complex between GFP–PAX3-FKHR
and the biotin-labeled wild-type PRO2. The specific
DNA- protein complex was disrupted by the inclu-
sion of a wild-type un-labeled PRO2 (lane 4), but
not by a mutated un-labeled PRO2m (lane 5). The
amount of GFP–PAX3-FKHR and GFP used in the
EMSA assay is shown in Figure 5B. Similar results
were obtained when in vitro-translated PAX3-FKHR
was used (Additional file 3: Figure S2). These results
indicate that PAX3-FKHR binds to the promoter
region of CPT1A in a PD binding site–dependent
manner, further confirming that CPT1A is a tran-
scriptional target of PAX3-FKHR.
CPT1A promotes cell motility in ARMS cells
To determine whether PAX3-FKHR’s regulation of
motility in ARMS cells is mediated by CPT1A, we first
Response
Element
Oligonucleotide sequence Nucleotide location
PRO1 -5’-ATTAcctgcctctctcGTTCT-3’ -6239to -6219
PRO1m -5’-ATTAcctgcctctctcATTTA-3’ -6239to -6219
PRO2 -5’-GTTACtcatcttcATTA-3’ -5391to -5375
PRO2m -5’-ATTTAtcatcttcATTA-3’ -5391to -5375
PRO3 -5’-GTTCTctgcttctttATTA-3’ -2387 to -2369
PRO3m -5’-ATTTActgcttctttATTA-3’ -2387 to -2369
PRO4 -5’-GTTCTtgacgctggaagaATTA3’ -716to -695









Figure 4 Functional analysis of the putative PAX3-FKHR response elements upstream of the CPT1A transcription start site (TSS). (A) The
putative binding sites (ie, PRO1, PRO2, PRO3 and PRO4) containing a composite PD (GTTC/AT/C) and HD (ATTA) recognition site and the
corresponding mutants with the PD site mutated (ie, PRO1m, PRO2m, PRO3m and PRO4m). Nucleotide locations are relative to the TSS. (B)
Transcriptional activity of putative PAX3-FKHR binding sites. NIH3T3 cells were transfected as indicated 24 hours prior to luciferase assays. TK is the
reporter without any PRO sequence and was used as a negative control. Data were expressed as relative luciferase units (RLUs) by normalizing
firefly luciferase activity to Renilla luciferase activity. PF, PAX3-FKHR.
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measured the effect of downregulating CPT1A on Rh30
cell motility in the wound-healing assay. CPT1A siRNA
reduced Rh30 cell motility by 33% (Figure 6A), whereas
PF siRNA reduced it by 67%. CPT1A siRNA has less
effect on wound-healing than PF siRNA, possibly
because other transcription targets of PAX3-FKHR also
play roles in regulating cell motility. The high efficiency
of siRNA-mediated CPT1A and PAX3-FKHR downre-
gulation is shown in Figure 6B. The effect of CPT1A
siRNA on cell motility was confirmed by using two dif-
ferent individual siRNAs, CPT1A siRNA 1 and CPT1A
siRNA 2 (Additional file 4: Figure S3A and S3B).
Whereas CPT1A siRNA significantly reduced Rh30 cell
motility, its effect on the cell growth of Rh30 is marginal
(Additional file 4: Figure S3C). We further confirmed
the effect of downregulating CPT1A on cell motility by
using Etomoxir, a pharmacologic inhibitor of CPT1 [24].
In published studies, etomoxir were used at 100 –
200 μM range in cell-based assays [24]. We tested a
range of etomoxir concentrations between 10 and
200 μM. Etomoxir decreased the motility of Rh30 cells
in a dose-dependent manner (Figure 7 and Additional
file 5: Figure S4A). The effect of etomoxir on cell motility
was significant only at higher concentration (Additional
file 5: Figure S4A), possibly because of the high level of
CPT1A present in Rh30 cells (Figure 3B). However, the
effect of etomoxir is specific to Rh30 cells – at all con-
centrations tested, etomoxir failed to reduce the cell
motility of RD (Additional file 5: Figure S4B), a PAX3-
FKHR-negative ERMS cell line with very low level of
CPT1A (Figure 3A and 3B). These results indicate that
downregulation of CPT1A, either by gene knockdown,
or by pharmacologic intervention, leads to decreased
cell motility in Rh30 cells. Taken together, these data
reveal a novel function of CPT1A in promoting cell
motility in ARMS.
Discussion
Intensive efforts have recently been made to identify the
signaling pathways involved in PAX3-FKHR–mediated
ARMS tumorigenesis, including efforts to identify the
transcription targets of PAX3-FKHR [1]. The rationale of
our study is that if the transcription targets of PAX3-FKHR
also mediate the function of PAX3-FKHR in regulating
ARMS tumorigenesis, then these PAX3-FKHR transcrip-
tion targets would be novel therapeutic targets for ARMS.
However, few genes have been commonly identified by
previous studies using different approaches [25]. Some
studies focused on induction of gene expression by overex-
pressing PAX3-FKHR in a non-ARMS background, how-
ever, ectopic expression of PAX3-FKHR might not lead to
induction of endogenous PAX3-FKHR target genes in a
non-ARMS environment. Other studies focused on genes
whose expression is present in PAX3-FKHR-positive
tumor samples but is absent in PAX3-FKHR–negative
tumor samples, however, PAX3-FKHR is not the only dif-
ference between these tumor samples [1,25]. In order to
identify transcriptional targets of PAX3-FKHR in an
ARMS cellular context, we used PAX3-FKHR-specific
shRNA to stably knockdown PAX3-FKHR in Rh30 cells.
In the PAX3-FKHR stable knockdown clones we used,
only 50% of PAX3-FKHR was knocked down, likely
because PAX3-FKHR positively regulates the cell growth
of Rh30 cells; therefore, complete knockdown of PAX3-
FKHR would significantly and negatively affect the growth
A




Labeled PRO2 + + + + +
B -GFP-PF
-GFP
Figure 5 PAX3-FKHR binds to the CPT1A promoter. (A) EMSA
analysis of GFP–PAX3-FKHR binding to CPT1A putative binding site 2
(PRO2). All lanes contain labeled PRO2 in addition to other
components, as indicated. 100-fold excess unlabeled wild-type
(PRO2) or PD-binding site mutant (PRO2m) was used to compete
with the labeled PRO2 DNA probe for GFP-PAX3-FKHR binding.
GFP-PF, nuclear extract prepared from HEK293T cells transfected with
GFP-PAX3-FKHR; GFP, nuclear extract prepared from HEK293T cells
transfected with GFP vector only. Arrow indicates the PAX-FKHR-
DNA complexes. (B) The amount of GFP-PF and GFP in the nuclear
extracts used for the EMSA, revealed by using an anti-GFP antibody
in a Western blot analysis.
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of Rh30 cells. Indeed, even with only 50% stable knock-
down of PAX3-FKHR in Rh30 cells, there is already a dras-
tic defect in anchorage-independent growth. Similarly, the
cell motility, as revealed by the wound healing assay,
decreases significantly in the stable knockdown clones.
The observations that PAX3-FKHR regulates ARMS cell
growth and cell motility were in agreement with those
made in previous studies of other ARMS cell lines
[2,19,20]. Because our knockdown clones had significant
defects in the function of PAX3-FKHR, we used them for
gene-profiling analysis. Among the genes whose expres-
sion was downregulated in the PAX3-FKHR knockdown
clone were CNR1, ALDH1A3, EYA2, MCTP2, MXRA5,
NTF3, OLIG1, SEPP1, SULF2, and TOX3 (Additional file
2: Table S1), genes previously shown to be target genes of
PAX3-FKHR in several independent studies [1,21], and
CPT1A, a novel transcriptional target gene of PAX3-
FKHR. CPT1A was not identified as a target gene of
PAX3-FKHR in other studies, most likely because of the




Figure 7 Inhibition of CPT1A decreases the motility of Rh30
cells. Wound healing assay was performed as described in Figure 2,





Figure 6 Downregulation of CPT1A decreases cell motility in Rh30 cells. (A) NT siRNA, PAX3-FKHR siRNA, or CPT1A siRNA (ON-TARGETplus
SMARTpool) was transfected into Rh30 cells, and wound healing assays were performed as described in Figure 2. (B) The knockdown efficiency
was confirmed by using real-time RT-PCR.
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significantly, downregulation of CPT1A causes defects in
cell motility, at least partially recapitulating the defects
caused by downregulation of PAX3-FKHR. In addition,
overexpression of PAX3-FKHR in either RD or NIH3T3
cells leads to moderate upregulation of CPT1A. Further-
more, PAX3-FKHR binds to the promoter region of
CPT1A in a PD binding site–dependent manner. There-
fore, our study identified CPT1A as a novel transcriptional
target of PAX3-FKHR that also carries out the function of
PAX3-FKHR in regulating cell motility.
CPT1 is a key regulatory enzyme regulating fatty-acid
oxidation and has been heavily studied as a therapeutic
target for the treatment of the metabolic syndrome [26].
A few recent reports also implicate the involvement of
CPT1 in regulating apoptosis and in cancer development
[27,28]. Despite decreased expression in the cytoplasm of
several tumor tissues, CPT1A expression was found to
localize in the nuclei, where it interacts with histone
deacetylase protein complexes in neoplastic cells [29]. A
recent study showed that CPT1C is frequently upregu-
lated in human lung tumor and that CPT1C depletion
via siRNA suppresses xenograft tumor growth in vivo,
suggesting that CPT1C may be a new therapeutic target
for the treatment of hypoxic tumors [10]. Another report
suggests that in prostate cancer, androgen upregulates
the mRNA level of CPT1, leading to increased mito-
chondrial oxidation of fatty acids and increased produc-
tion of reactive oxygen species known to be associated
with prostate cancer cell proliferation [30]. The role of
CPT1 in regulating cancer cell proliferation appears to
be emerging. Our study identifies CPT1A as a transcrip-
tional target of PAX3-FKHR. Furthermore, downregula-
tion of CPT1A at least partially mimics the effect of
downregulating PAX3-FKHR, providing a functional link
between PAX3-FKHR and CPT1A in regulating cell mo-
tility in ARMS. This is the first evidence that CPT1A
positively contributes to the regulation of cancer cell
motility.
Conclusions
In conclusion, our goal was to identify druggable transcrip-
tion targets of PAX3-FKHR that are also downstream
effectors of PAX3-FKHR–mediated cell motility. We pro-
vide evidences that CPT1A is such a transcriptional target
of PAX3-FKHR that also regulates cell motility. Pharmaco-
logic modulator of CPT1 is available, and CPT1 has been
studied as a therapeutic target for the treatment of the
metabolic syndrome [26]. Our study revealed the novel
function of CPT1A in promoting cell motility, and sug-
gests that CPT1A [4] could be a novel therapeutic target
for ARMS. However, how CPT1A regulates cell motility is
still unclear. Future efforts should be directed to better
understand the molecular mechanism responsible for
CPT1A-mediated cell motility, in order to facilitate the full
validation of CPT1A as a novel therapeutic target for the
treatment of ARMS.
Additional files
Additional file 1: Figure S1. Downregulation of PAX3-FKHR slightly
decreases the growth rate of Rh30 cells. Cell growth of Rh30 control
clone (CON) and PAX3-FKHR knockdown clones (KD1 and KD2) was
monitored by using the IncuCyte live-cell imaging system, and was
expressed as % of cell confluence as defined by the IncuCyte software.
Additional file 2: Table S1. Genes downregulated when PAX3-FKHR
is downregulated.
Additional file 3: Figure S2. In vitro EMSA analysis of PAX3-FKHR
binding to CPT1A putative binding site 2 (PRO2). All lanes contain
labeled PRO2 in addition to other components, as indicated. 100-fold
excess unlabeled wild-type (PRO2) or PD-binding site mutant (PRO2m)
was used to compete with the labeled PRO2 DNA probe for PAX3-FKHR
binding. PF, in vitro translated PAX3-FKHR. Arrow indicates the PAX3-
FKHR-PRO2 complexes. The amount of PAX3-FKHR used for the EMSA
was shown in the lower panel in a Western blotting analysis using anti-
FKHR antibodies.
Additional file 4: Figure S3. Downregulation of CPT1A decreases
cell motility in Rh30 cells. (A) Individual CPT1A siRNA (1 or 2) was
transiently transfected into Rh30 cells. Wound healing assays were
performed as described in Figure 2. (B) The knockdown efficiency was
revealed by using real-time RT-PCR. (C) CPT1A siRNA does not
significantly affect cell growth.
Additional file 5: Figure S4. Etomoxir decreases the motility of
Rh30, but not RD cells. Rh30 (A) or RD (B) cells were treated with
different concentration of etomoxir and cell motility was monitored at
different time points as indicated. Wound healing assays were performed
as described in Figure 2.
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